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Inﬂuence of Anti–Tumor Necrosis Factor Therapy
on Cancer Incidence in Patients With Rheumatoid
Arthritis Who Have Had a Prior Malignancy:
Results From the British Society for Rheumatology
Biologics Register
W. G. DIXON, K. D. WATSON, M. LUNT, L. K. MERCER, BRITISH SOCIETY FOR RHEUMATOLOGY
BIOLOGICS REGISTER CONTROL CENTRE CONSORTIUM, K. L. HYRICH, AND D. P. M. SYMMONS,
ON BEHALF OF THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER
Objective. To explore the inﬂuence of anti–tumor necrosis factor (anti-TNF) therapy upon the incidence of cancer in
patients with rheumatoid arthritis (RA) and prior malignancy.
Methods. Using data from the British Society for Rheumatology Biologics Register, a national prospective observational
study established in 2001, we identiﬁed 293 patients with a prior malignancy from over 14,000 patients with RA. We
compared rates of incident malignancy in 177 anti-TNF–treated patients and 117 patients with active RA treated with
traditional disease-modifying antirheumatic drugs (DMARDs), all with prior malignancy. One patient switched therapy
and contributed to both cohorts.
Results. The rates of incident malignancy were 25.3 events/1,000 person-years in the anti-TNF cohort and 38.3/1,000
person-years in the DMARD cohort, generating an age- and sex-adjusted incidence rate ratio of 0.58 (95% conﬁdence
interval 0.23–1.43) for the anti-TNF–treated cohort compared with the DMARD cohort. Of the patients with prior
melanomas, 3 (18%) of 17 in the anti-TNF cohort developed an incident malignancy, compared with 0 of 10 in the DMARD
cohort.
Conclusion. The way in which UK rheumatologists are selecting patients with RA and prior malignancy to receive
anti-TNF therapy is not leading to an increased risk of incident malignancy. Although reassuring, these results should not
be interpreted as indicating that it is safe to treat all RA patients with prior malignancy with anti-TNF therapy.
INTRODUCTION
Tumor necrosis factor (TNF) is a pivotal cytokine in the
inﬂammatory synovium of patients with rheumatoid ar-
thritis (RA). This discovery led to the successful develop-
ment of anti-TNF therapy, thereby signiﬁcantly advancing
drug treatment for patients with RA. Although important
in the pathophysiology of RA, TNF also has many physi-
ologic roles, including host defense and tumor surveil-
lance (1). Therefore, despite good proven efﬁcacy, there
have always been concerns about the safety of anti-TNF
therapy.
The exact relationship between TNF and cancer is un-
clear. At high doses, TNF has been used as a treatment for
some malignancies, including melanoma and sarcoma (2).
Conversely, anti-TNF therapy has been suggested as a pos-
sible treatment for cancer-associated cachexia (3,4). It is
plausible that TNF has different roles at different concen-
trations during different stages of tumor genesis. Similarly,
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755anti-TNF therapy may have a spectrum of inﬂuence upon
de novo malignancy, carcinoma in situ (CIS), and preex-
isting malignancy.
The hypothetical increased risk of new or recurrent ma-
lignancy in patients with prior malignancy led researchers
to exclude such patients from randomized clinical trials of
anti-TNF therapy for RA (5–7). Clinical trial data and
open-label extension studies are thus limited in their abil-
ity to address the question of whether anti-TNF therapy
inﬂuences the malignancy rate in patients with prior can-
cer. Observational studies are similarly limited by the
usual clinical practice, often inﬂuenced by local or na-
tional guidelines (8,9). In the UK, the British Society for
Rheumatology (BSR) guidelines for anti-TNF prescription
state that “caution should be exercised in the use of anti-
TNF therapies in patients with previous malignancy. The
potential beneﬁts of treatment need to be considered
against the risks related to potential recurrence of the
speciﬁc malignancy. If patients have been free of any re-
currence of their malignancy for 10 years there is no evi-
dence for a contraindication to anti-TNF therapy” (8). The
potential harm of anti-TNF therapy in patients with RA
with prior malignancy has never been quantiﬁed, making
an evidence-based calculation of the beneﬁt/harm balance
impossible. The aim of this study, therefore, was to ex-
plore the inﬂuence of anti-TNF therapy on the incidence of
cancer in patients with RA and prior malignancy.
PATIENTS AND METHODS
The subjects for this analysis were participating in a large
national prospective observational study, the BSR Biolog-
ics Register (BSRBR). The methods have been described in
detail elsewhere (10). In brief, the study was established in
2001 in order to examine the long-term safety of biologic
drugs. UK national guidelines recommended that anti-
TNF drugs should be reserved for patients with active RA
(Disease Activity Score in 28 joints [DAS28] 5.1) despite
previous therapy with at least 2 disease-modifying anti-
rheumatic drugs (DMARDs), and that “any clinician pre-
scribing these medications must (with the patient’s per-
mission) undertake to register the patient with the
[BSRBR] and forward information on dosage, outcome and
toxicity on a six-monthly basis” (11). Recruitment targets
of 4,000 patients for the 3 anti-TNF drugs etanercept, in-
ﬂiximab, and adalimumab were met in 2005, 2007, and
2008, respectively. No accurate ﬁgures for anti-TNF pene-
tration in the UK RA population exist, although estimates
of 7% have been suggested (12). Before recruitment tar-
gets were met, we estimated that 80% of anti-TNF–
treated patients with RA in the UK were registered with
the BSRBR. Ethical approval for this study was obtained in
December 2000 from the Multicentre Research Ethics
Committee for the Northwest of England.
Anti-TNF cohort. Analysis was restricted to patients
registered with the BSRBR with a physician diagnosis of
RA who were commencing an anti-TNF drug as their ﬁrst
biologic drug. Patients registered 6 months after the start
of biologic agent therapy were excluded. All patients in
this study were registered prior to September 30, 2007.
Comparison cohort. A cohort of patients who had never
taken biologic agents and had active RA was being re-
cruited in parallel (Appendix A) and followed with iden-
tical methodology (10). These patients had a physician
diagnosis of RA with active disease (guideline DAS28
4.2) despite current treatment with a traditional
DMARD, and had never taken biologic agents. Comparison
patients also had to be registered prior to September 30,
2007.
Identiﬁcation of prior malignancy. Analysis was lim-
ited to patients with prior malignancy. At registration, all
patients were linked to the UK National Health Service
Information Centre (NHS IC; formerly the Ofﬁce for Na-
tional Statistics), which collates data from the 8 regional
English cancer registries, in addition to similar registers in
Wales, Scotland, and Northern Ireland. This provided de-
tails of all historic cancers, including date of diagnosis,
type, and anatomic site. Prior malignancies were deﬁned
as malignancies identiﬁed by the NHS IC with a diagnosis
date prior to the ﬁrst dose of anti-TNF therapy, or prior to
the registration date for the comparison cohort. CIS and
nonmelanoma skin cancer were excluded. Where patients
had 1 prior malignancy, the most recent malignancy was
reported.
Baseline assessment. Baseline information for both co-
horts included demographics, disease duration, 28 swol-
len and 28 tender joint counts, erythrocyte sedimentation
rate and/or C-reactive protein level, and patient global
assessment, which enables calculation of a DAS28 score
(13). Patients completed a Health Assessment Question-
naire (HAQ) adapted for British use (14). Details of all
previous and current DMARD therapy and all other cur-
rent medication were obtained, as well as smoking history
and comorbidity.
Followup. Data on the occurrence of adverse events
were captured in 3 ways: 6-monthly rheumatologist ques-
tionnaire, 6-monthly patient diary, and by ﬂagging with
the NHS IC, who provided information on incident malig-
nancy and mortality, including cause of death (coded ac-
cording to the International Classiﬁcation of Diseases,
Tenth Revision). It has been estimated that the NHS IC
accurately captures 90% of incident cancers (15). After 3
years of followup, consultant questionnaires were sent
annually, and patient diaries were no longer sent.
Deﬁnition of incident malignancy. Incident malignan-
cies were deﬁned as malignancies diagnosed after the ﬁrst
dose of anti-TNF therapy for the anti-TNF cohort, or after
the registration date for the DMARD cohort. New prima-
ries, local recurrence, and metastases were all included as
incident cancers. CIS and nonmelanoma skin cancer were
excluded, as were benign cancers and malignancies
known to be present on the date of registration.
Veriﬁcation of incident malignancy. If cancers were re-
ported from any source, clinicians were asked to provide
further information for these events. Cancers were catego-
756 Dixon et alrized as deﬁnite if there was histologic conﬁrmation or if
they were reported by the NHS IC. Cancers were catego-
rized as probable if the patients received deﬁnite antican-
cer treatment such as chemotherapy or radiotherapy, if
there was diagnostic imaging, if there was direct visual-
ization of the tumor, or if the malignancy was reported on
the death certiﬁcate. Other cancers were labeled as possi-
ble if they were consultant reported and did not fulﬁll the
above criteria. Cancers reported by the patient without any
further veriﬁcation from the rheumatologist or NHS IC
were excluded. All supporting information was indepen-
dently reviewed by 2 clinicians (WGD and LKM). Any
disagreement about veriﬁcation category was resolved by
discussion.
Statistical analysis. Followup time was calculated from
the date of the ﬁrst anti-TNF drug use for the anti-TNF–
treated cohort, or from the registration date for the com-
parison cohort, to September 30, 2007 or the death date,
whichever occurred ﬁrst. Malignancy data were captured
from all 3 sources until April 2008 to allow for delays in
notiﬁcation of incident malignancies to the BSRBR.
Within the anti-TNF cohort, patients could switch be-
tween anti-TNF drugs. The anti-TNF cohort contributed
person-years of followup even if the anti-TNF therapy was
stopped. Malignancies were attributed to anti-TNF therapy
irrespective of drug discontinuation. In other words, ma-
lignancies occurring both during active anti-TNF therapy
and after stopping anti-TNF therapy were attributed to the
anti-TNF cohort. Patients ever treated with a non–anti-
TNF biologic drug (e.g., anakinra or rituximab) were ex-
cluded completely from the analysis. Patients initially reg-
istered in the comparison cohort who subsequently
received an anti-TNF drug contributed person-years to the
comparison cohort up to the date that the anti-TNF drug
was started, and contributed subsequent followup to the
anti-TNF cohort.
Patients could develop a second or subsequent malig-
nancy following the date of their ﬁrst incident malignancy.
Followup was therefore not censored at the time of inci-
dent cancer diagnosis. However, a sensitivity analysis was
conducted, excluding time and events after the ﬁrst malig-
nancy. The inﬂuence of time since prior malignancy was
examined by stratifying the data according to time since
prior cancer (more or less than 10 years).
Malignancy rates are presented as events/1,000 person-
years with 95% conﬁdence intervals (95% CIs). Incidence
rate ratios (IRRs) were calculated using Cox regression,
comparing between the anti-TNF cohort and the DMARD
cohort. Adjustment was made for age and sex. A propen-
sity score was calculated based on age, sex, disease dura-
tion, baseline DAS28 and HAQ scores, year of entry, and
smoking status. Propensity-adjusted estimates were calcu-
lated by stratifying the propensity score into deciles. Mul-
tiple imputation was used to avoid bias caused by missing
data (there were 3 subjects with missing disease duration,
5 with missing DAS28, and 32 with missing HAQ score).
Nelson-Aalen cumulative incidence plots were generated
to explore time-dependent incidence in the two cohorts.
All analysis was done using Stata, versions 9.2 and 10.1
(Stata).
RESULTS
Of the patients, 10,735 received anti-TNF therapy and no
other biologic agent therapy. The initial anti-TNF drug was
etanercept for 3,971 patients, inﬂiximab for 3,352 patients,
and adalimumab for 3,412 patients. The comparison co-
hort consisted of 3,235 DMARD-treated patients. After
linkage with the NHS IC, 293 patients with a prior history
of malignancy (excluding CIS and nonmelanoma skin can-
cer) were identiﬁed, 177 (1.6%) of 10,735 in the anti-TNF
cohort and 117 (3.6%) of 3,235 in the comparison cohort
(Figure 1). One patient who originally registered in the
DMARD cohort started anti-TNF therapy and therefore
contributed person-years to both cohorts. All subsequent
analyses are restricted to these patients. Of the 177 pa-
tients in the anti-TNF cohort, 46 received 1 anti-TNF
drug.
The baseline characteristics are shown in Table 1. The
anti-TNF cohort was younger, comprised of proportionally
more women, and, as expected, had more severe disease
than the comparison cohort. The anti-TNF cohort was
more likely to be receiving steroids at baseline, and in-
cluded fewer current or former smokers. Subtypes of prior
malignancy were balanced in the two cohorts. Approxi-
mately 80% of the prior malignancies were solid tumors,
with the remainder approximately divided into lympho-
proliferative malignancies and melanomas. Proportionally
more prior malignancies were diagnosed 10 years before
Figure 1. Flow chart of patients in study. RA  rheumatoid
arthritis; anti-TNF  anti–tumor necrosis factor; DMARD  dis-
ease-modifying antirheumatic drug; NMSC  nonmelanoma skin
cancer; CIS  carcinoma in situ.
Anti-TNF Therapy in Patients With a History of Cancer 757registration for the anti-TNF cohort (58%) compared with
the DMARD cohort (39%).
The total followup time was 750 person-years: 515 for
the anti-TNF cohort and 235 for the DMARD cohort. Pa-
tients in the anti-TNF cohort contributed a median fol-
lowup time of 3.1 person-years, compared with 1.9 person-
years for patients in the DMARD cohort. Only 12 (4%) of
293 patients had no returned consultant questionnaires
during their followup.
There were 13 incident malignancies in 11 patients
identiﬁed in the anti-TNF cohort compared with 9 malig-
nancies in 9 patients in the DMARD cohort (Table 2 and
Figure 2). There were no patient-reported malignancies
that were not veriﬁed by a consultant. The resultant rates
of malignancy were 25.3 events/1,000 person-years in the
anti-TNF cohort and 38.3 events/1,000 person-years in the
DMARD cohort. The age- and sex-adjusted IRR was 0.58
(95% CI 0.23–1.43) for the anti-TNF–treated patients com-
pared with the DMARD cohort. The propensity-adjusted
estimate was 0.45 (95% CI 0.09–2.17). A sensitivity ana-
lysis, censoring followup at the ﬁrst incident malignancy,
resulted in an age- and sex-adjusted IRR of 0.52 (95% CI
Table 1. Baseline characteristics*
DMARD
(n  117)
All anti-TNF
(n  177) P
Age, mean  SD years 66  10 62  10 0.002
Women, % 74 81 0.110
DAS28, mean  SD 5.0  1.3 6.7  1.2 0.0001
HAQ score, mean  SD 1.6  0.7 2.2  0.5 0.0001
Disease duration, median (IQR) years 9 (2–18) 11 (6–18) 0.0083
Prior DMARDs, median (IQR) 2 (1–4) 4 (3–5) 0.0001
Baseline steroid use 39 (33) 90 (51) 0.003
Smoking
Current 25 (21) 32 (18) 0.011
Former 61 (52) 67 (38)
Never 31 (27) 77 (44)
Entry year
Pre-2003 0 15 (8)  0.0001
2003 6 (5) 57 (32)
2004 27 (23) 49 (28)
2005 41 (35) 28 (16)
2006 or after 43 (37) 28 (16)
Prior malignancy
Solid 96 (82) 147 (83) 0.795
Lymphoproliferative 11 (9) 13 (7)
Melanoma 10 (8) 17 (10)
Time from most recent prior malignancy to
registration
Median (IQR) years 8.5 (4.7–14.1) 11.5 (5.8–17.1) 0.027
10 years preregistration 46 (39) 102 (58) 0.002
* Values are the number (percentage) unless otherwise indicated. DMARD  disease-modifying antirheu-
matic drug; anti-TNF  anti–tumor necrosis factor; DAS28  Disease Activity Score in 28 joints; HAQ 
Health Assessment Questionnaire; IQR  interquartile range.
Table 2. Rate of incident cancers in patients with prior malignancy*
DMARD
(n  117)
All anti-TNF
(n  177)
Person-years of followup 235 515
Person-years of followup per patient,
median (IQR)
1.9 (1.3–2.7) 3.1 (2.0–3.9)
Incident malignancies, no. 9 13
Patients with incident malignancies, no. 9 11
Rate of incident malignancy/1,000
person-years (95% CI)
38.3 (17.5–72.7) 25.3 (13.4–43.2)
IRR (95% CI) Referent 0.56 (0.23–1.35)
IRR adjusted for age and sex (95% CI) Referent 0.58 (0.23–1.43)
Propensity-adjusted IRR (95% CI) Referent 0.45 (0.09–2.17)
* DMARD  disease-modifying antirheumatic drug; anti-TNF  anti–tumor necrosis factor; IQR 
interquartile range; 95% CI  95% conﬁdence interval; IRR  incidence rate ratio.
758 Dixon et al0.21–1.33) and a propensity-adjusted IRR of 0.47 (95% CI
0.10–2.22) (Table 3). Stratifying by time since prior malig-
nancy did not reveal any effect measure modiﬁcation. The
age- and sex- adjusted IRR was 0.71 (95% CI 0.18–2.79) for
malignancies that occurred 10 years prior to registration,
and was 0.63 (95% CI 0.10–4.11) for malignancies 10
years prior to registration.
A clinical table of the timings and anatomic sites of the
prior and incident malignancies is shown in Table 4. Of
the 6 patients with a malignancy 10 years prior to start-
ing anti-TNF therapy who later developed an incident
malignancy, 3 had a prior melanoma. Three (18%) of the
17 patients with prior melanomas in the anti-TNF cohort
developed an incident malignancy, compared with 0 of 10
in the DMARD cohort.
DISCUSSION
We have shown that in patients with RA and prior malig-
nancy, the rate of incident malignancy is not increased in
patients selected to receive anti-TNF therapy after an av-
erage of 3 years of followup. The age- and sex-adjusted IRR
was 0.58 (95% CI 0.23–1.43) for the anti-TNF–treated co-
hort compared with the DMARD cohort. This ﬁnding is
very reassuring at face value. However, it must be inter-
preted with great care in the context of an observational
drug study. We must carefully consider the potential se-
lection factors and biases, and try to understand how they
might inﬂuence the result.
A major potential bias in this analysis is selection bias.
When considering further management for a patient with
active RA and prior malignancy, clinicians make a treat-
ment decision based upon available information. They
may be more inclined to prescribe anti-TNF therapy if the
prior malignancy had a good prognosis. Examples may
include prior cancers with a long period in remission,
complete surgical excision, or a “low-grade” tumor. In
contrast, patients with prior malignancies who had a
higher chance of recurrence or metastasis may have had
anti-TNF therapy rejected based upon the hypothetical
increased risk conferred by the drug. This may lead to an
imbalance in the baseline risk of incidence malignancy
between the two cohorts, partially explaining the lower
rate in the anti-TNF–treated cohort. This hypothesis is
supported by the higher proportion of DMARD-treated
patients with a prior malignancy 10 years prior to the
registration date. Although the broad subtypes of prior
malignancy were balanced in the two cohorts, we do not
have detailed information about these prior cancers. An-
other possible imbalance was differential cancer screening
prior to study entry between the cohorts treated with anti-
TNF therapy and DMARDs. Unfortunately, no information
was available on the type or extent of screening in the two
cohorts. We cannot know, therefore, whether the likeli-
hood of recurrence differed between the two groups ac-
cording to the stage, severity, or histology of the original
malignancies. Nonetheless, this is the only study setting
that can feasibly address this clinically important ques-
tion. Randomized controlled trials are too small, too short,
and exclude the patients of interest. Spontaneous pharma-
covigilance studies provide an inaccurate numerator, no
denominator, and no comparison cohort.
Following registration, the method of followup was
identical for the two cohorts. Any diagnosed incident ma-
lignancies would have been reported to the BSRBR with
equal likelihood in the two cohorts. There remains the
possibility of surveillance bias, in which patients in the
anti-TNF cohort have more frequent followup appoint-
Figure 2. Cumulative incidence of malignancy in patients with
prior malignancy by Nelson-Aalen plot. DMARD  disease-mod-
ifying antirheumatic drug; anti-TNF  anti–tumor necrosis factor.
Table 3. Sensitivity analysis: rate of incident cancers in patients with prior malignancy:
followup censored after ﬁrst incident malignancy*
DMARD
(n  117)
All anti-TNF
(n  177)
Person-years of followup 232 503
Person-years followup per patient,
median (IQR)
1.8 (1.3–2.6) 3.0 (1.9–3.9)
Incident malignancies, no. 9 11
Patients with incident malignancies, no. 9 11
Rate of incident malignancy/1,000
person-years (95% CI)
38.7 (17.7–73.5) 21.9 (10.9–39.2)
IRR (95% CI) Referent 0.51 (0.2–1.27)
IRR adjusted for age and sex (95% CI) Referent 0.52 (0.21–1.33)
Propensity-adjusted IRR (95% CI) Referent 0.47 (0.10–2.22)
* DMARD  disease-modifying antirheumatic drug; anti-TNF  anti–tumor necrosis factor; IQR 
interquartile range; 95% CI  95% conﬁdence interval; IRR  incidence rate ratio.
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760 Dixon et alments and/or closer clinical scrutiny of new symptoms
that might then be diagnosed as an incident malignancy.
Such a bias, however, would elevate the rate in the anti-
TNF cohort and does not explain our ﬁndings.
The differential duration of followup may have an im-
pact on our results. Patients in the anti-TNF–treated cohort
were followed up for just over 3 years compared with
nearly 2 years for the DMARD cohort. This differential
followup time is important only if the rate of cancer
changes with time. The cumulative incidence plot in Fig-
ure 2 suggests that the rate may accelerate with increasing
duration of followup: a possible explanation being a pre-
registration screen for malignancy that wears off with in-
creasing followup. However, if this increasing rate of ma-
lignancy with time is true, extending followup in the
DMARD cohort would further increase the rate of incident
malignancy in this cohort. Once again, this potential bias
does not explain our ﬁndings of a lower rate in the anti-
TNF–treated cohort. Although it is important to consider
time-dependent risk, the number of events was too low to
generate any meaningful sensitivity analysis by time
bands.
One of the strengths of the BSRBR is its size. It is a
national prospective observational study that includes
14,000 patients with RA. Despite this, there were only
293 patients with prior cancer. Only 20 patients developed
an incident cancer, limiting the power of the study. The
point estimate for the IRR of 0.58 (95% CI 0.23–1.43) has
wide 95% CIs, and we cannot be certain of an absence of
an increased risk. However, this ﬁnding is our current best
estimate to address an important clinical question. Despite
the wide 95% CIs, this study adds useful information to an
area with no prior evidence base.
The reported IRR was adjusted only for age and sex. The
low number of incident malignancies limits further adjust-
ment for potential confounders, following the statistical
rule that no more than 1 variable should be included in the
model per 10 events (16). We must therefore consider
whether our results might be explained by residual or
unmeasured confounding. The addition of calendar year to
the analysis did not change the point estimate. High dis-
ease severity is associated with certain malignancies such
as lymphoma (17). The imbalance of disease severity at
baseline therefore might be expected to increase the ma-
lignancy rate in the anti-TNF–treated cohort, which would
not explain our ﬁndings. The higher proportion of patients
who had ever smoked in the DMARD cohort may go some
way to explain their higher malignancy rate. Other vari-
ables such as steroid use were also imbalanced. Although
it is difﬁcult to statistically adjust for these potential con-
founders, it seems unlikely that residual confounding
would explain the magnitude of differential risk in the two
cohorts. This is supported by the propensity-adjusted ana-
lyses not changing the results. We have previously shown
socioeconomic status (SES) in anti-TNF–treated patients
to closely reﬂect the general population distribution (18).
The lack of association between SES and anti-TNF expo-
sure means that SES cannot be a confounder.
One way of tackling multiple potential confounders and
a low number of outcomes is to use a propensity score. We
undertook such an analysis, and adjusting for the propen-
sity score made very little difference to the result.
Prior malignancies were identiﬁed using linkage with
the NHS IC. It is possible that some patients with prior
malignancy were not identiﬁed due to an administrative
delay from clinical diagnosis to notiﬁcation from the NHS
IC to the BSRBR, and therefore were not included in this
analysis. However, such patients should not be systemat-
ically different from those included in the study and
would not affect the validity of the ﬁndings.
Previous reports from the BSRBR have limited analysis
to periods with returned consultant followup (19). For this
analysis, by using an “ever had drug” model of analysis,
followup time beyond the last returned consultant fol-
lowup questionnaire was also included because malignan-
cies could still be captured robustly from patient diaries
and the NHS IC. We continued data capture for 6 months
beyond the study cutoff date to maximize data return from
all sources.
All incident malignancies were attributed to anti-TNF in
patients in the anti-TNF cohort whether or not they con-
tinued the drug. Other options would be to restrict analy-
sis to malignancies that were diagnosed while the patient
was either actively receiving the drug, or within a lag
window of risk beyond the stop date (19). We elected to
use an “ever had drug” model because, if there is an
association between anti-TNF therapy and malignancy,
the clinical latency is not known.
All incident malignancies were consultant reported. Of
the 22 reported cancers, 16 were deﬁned as deﬁnite and 6
as probable. None were deﬁned as possible. These results
are very reassuring. Despite not all malignancies being
deﬁned as deﬁnite, there was strong supporting evidence
for all incident malignancies in the analysis.
It is possible that malignancies identiﬁed early in the
course of followup may have been preexisting but as yet
undiagnosed. Only one incident malignancy was diag-
nosed in the ﬁrst 6 months of followup (patient #11).
Exclusion of this event from the anti-TNF cohort would
further reduce the IRR, supporting the absence of an in-
creased risk with anti-TNF therapy.
Two patients had 1 incident malignancy. Patient #3
had a melanoma 3.5 years prior to anti-TNF therapy, fol-
lowed by bladder cancer 2.4 years after starting therapy. If
followup was censored here, we would miss the pleural
melanoma diagnosed after 3.9 years. This may represent a
recurrence of the original primary, and is therefore an
important case. We did perform a sensitivity analysis ex-
cluding time after the ﬁrst malignancy, which did not
signiﬁcantly alter our point estimate. Only one of the pa-
tients who developed an incident malignancy had 1
prior cancer. Patient 12 in the DMARD cohort had both
non-Hodgkin’s lymphoma and bladder cancer prior to reg-
istration.
An interesting question to address would have been the
relative likelihood of deﬁnite recurrence or metastasis of
the original primary cancer. Unfortunately, despite strin-
gent efforts to collect as much information about both the
prior and incident malignancies, deﬁnite links could not
often be made due to a lack of histologic information. For
instance, it is possible that the cerebral metastases in pa-
Anti-TNF Therapy in Patients With a History of Cancer 761tient 2 were either related or not related to the prior mel-
anoma. Because no postmortem was conducted, this infor-
mation was not available. Any such analysis would
therefore be subject to a signiﬁcant degree of uncertainty.
No previous published studies have been able to address
the question as to whether anti-TNF therapy inﬂuences the
rate of malignancy in patients with prior malignancy.
Studies have been undertaken to understand whether anti-
TNF therapy increases the rate of de novo malignancy. The
results of such studies have ranged from no increased risk
in observational studies to a 3-fold increased risk in
meta-analyses of randomized controlled trials. These ﬁnd-
ings have been reviewed elegantly elsewhere (20). Our
suggestion that patients with prior melanoma may be at
particular risk of incident malignancy ﬁts with the existing
literature. Supraphysiologic doses of TNF have been used
to treat melanomas (2), suggesting that anti-TNF therapy
may be disadvantageous. An observational study from the
National Data Bank for Rheumatic Diseases also found an
increased risk of melanoma in patients treated with anti-
TNF therapy, although the overall risk of malignancy was
not increased (21). This further supports a possible mela-
noma-speciﬁc risk.
In summary, we have shown that the way in which UK
rheumatologists are selecting their patients with RA and
prior malignancy to receive anti-TNF therapy is not lead-
ing to an increased risk of incident malignancy over the
period of followup studied. The results should not be
interpreted as indicating that it is safe to treat all RA
patients with prior malignancy with anti-TNF therapy.
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